Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 10—October 2003
Perspective

Syndromic Surveillance and Bioterrorism-related Epidemics

James W. Buehler*Comments to Author , Ruth L. Berkelman*, David M. Hartley†, and Clarence J. Peters‡
Author affiliations: *Emory University Rollins School of Public Health, Atlanta, Georgia, USA; †University of Maryland School of Medicine, Baltimore, Maryland, USA; ‡University of Texas Medical Branch, Galveston, Texas, USA

Main Article

Figure 2

Timeline to presumptive anthrax diagnosis, 11 patients with inhalational anthrax, 2001, United States. Abbreviations: Dx, diagnosis; OutPt, outpatient visit followed by discharge home; ER, emergency room visit followed by discharge home. *Diagnosis delayed—initial blood cultures were negative in three patients who received antibiotic therapy before culture specimens were collected, requiring use of special diagnostic tests. For patients 1–10, case numbers correspond to those in report by Jerniga

Figure 2. Timeline to presumptive anthrax diagnosis, 11 patients with inhalational anthrax, 2001, United States. Abbreviations: Dx, diagnosis; OutPt, outpatient visit followed by discharge home; ER, emergency room visit followed by discharge home. *Diagnosis delayed—initial blood cultures were negative in three patients who received antibiotic therapy before culture specimens were collected, requiring use of special diagnostic tests. For patients 1–10, case numbers correspond to those in report by Jernigan et al. (13); patient 11 reported by Barakat et al. (14). A, timeline begins with presumed date of anthrax exposure, available for six patients. B, timeline begins with day of illness onset for five patients without recognized date of exposure.

Main Article

References
  1. Lazarus  R, Kleinman  KP, Dashevsky  I, DeMaria  A, Platt  R. Using automated medical records for rapid identification of illness syndromes (syndromic surveillance): the example of lower respiratory infection. BMC Public Health. 2001;1:9. DOIPubMedGoogle Scholar
  2. Mostashari  F. BT surveillance in New York City. Presentation at the CDC International Conference on Emerging Infectious Diseases, 2002, Atlanta. [Cited January 2003] Available from: URL: ftp://ftp.cdc.gov/pub/infectious_diseases/iceid/2002/pdf/mostashari.pdf
  3. Wagner  MM, Tsui  F, Espino  JU, Dato  VM, Sittig  DF, Caruana  RA, The emerging science of very early detection of disease outbreaks. J Public Health Manag Pract. 2001;7:51–9.PubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. Draft framework for evaluating syndromic surveillance systems for bioterrorism preparedness. [Cited December 2002] Available from: URL: http://www.cdc.gov/epo/dphsi/phs/syndromic.htm
  5. Committee on Science and Technology for Countering Terrorism, National Research Council of the National Academies. Making the nation safer, the role of science and technology in countering terrorism. Washington: National Academies Press; 2002. p. 74–6.
  6. Henning  KJ. Syndromic surveillance. In: Smolinski MS, Hamburg MA, Lederberg J, editors. Microbial threats to health, emergence, detection, and response. Washington: Institute of Medicine National Academies Press; 2003. Appendix B.
  7. Lewis  MD, Pavlin  JA, Mansfield  LJ, O’Brien  S, Boomsma  LG, Elbert  Y, Disease outbreak detection system using syndromic data in the greater Washington DC area. Am J Prev Med. 2002;23:180–6. DOIPubMedGoogle Scholar
  8. Broad  WJ, Miller  J. Health data monitored for bioterror warning. New York Times, Jan 27, 2003, page A1. [Cited Feb 2003]. Available from: URL: http://www.nytimes.com/2003/01/27/national/27DISE.html
  9. Centers for Disease Control and Prevention. Press release. CDC provides $1.2 million to fund pilot program for early warning system for terrorism-related illness outbreaks. [Cited Dec 2002] Available from: URL: http://www.cdc.gov/od/oc/media/pressrel/r021002.htm
  10. Reingold  A. If syndromic surveillance is the answer, what is the question? Biosecurity and Bioterrorism. Biodefense Strategy, Practice, and Science. 2003;1:1–5.
  11. Rotz  LD, Khan  AS, Lillibridge  SR, Ostroff  SM, Hughes  JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8:225–30. DOIPubMedGoogle Scholar
  12. Inglesby  TV, O’Toole  T, Henderson  DA, Bartlett  JG, Ascher  MS, Eitzen  E, Anthrax as a biological weapon, 2002, updated recommendations for management. JAMA. 2002;287:2236–52. DOIPubMedGoogle Scholar
  13. Jernigan  JA, Stephens  DS, Ashford  DA, Omenaca  C, Topiel  MS, Galbraith  M, Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933–44. DOIPubMedGoogle Scholar
  14. Barakat  LA, Quentzel  HL, Jernigan  JA. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA. 2002;287:863–8. DOIPubMedGoogle Scholar
  15. Bush  LM, Abrams  BH, Beall  A, Johnson  CC. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med. 2001;345:1607–10. DOIPubMedGoogle Scholar
  16. Borio  L, Frank  D, Mani  V, Chiriboga  C, Pollman  M, Ripple  M, Death due to bioterrorism-related inhalational anthrax, report of 2 patients. JAMA. 2001;286:2554–9. DOIPubMedGoogle Scholar
  17. Mayer  TA, Bersoff-Matcha  S, Murphy  C, Earls  J, Harper  S, Pauze  D, Clinical presentation of inhalational anthrax following bioterrorism exposure, report of 2 surviving patients. JAMA. 2001;286:2549–53. DOIPubMedGoogle Scholar
  18. Dewan  PK, Fry  AM, Laserson  K, Tierney  BC, Quinn  CP, Hayslett  JA, Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis. 2002;8:1066–72.PubMedGoogle Scholar
  19. Jernigan  DB, Raghunathan  PL, Bell  BP, Brechner  R, Bresnitz  EA, Butler  JC, Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019–28.PubMedGoogle Scholar
  20. Kuehert  MJ, Doyle  TJ, Hill  HA, Bridges  CB, Jernigan  JA, Dull  PM, Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis. 2003;36:328–36. DOIPubMedGoogle Scholar
  21. Sartwell  PE. The distribution of the incubation periods of disease (historical paper). Am J Epidemiol. 1995;141:386–94.PubMedGoogle Scholar
  22. Dennis  DT, Inglesby  TV, Henderson  DA, Bartlett  JG, Ascher  MS, Eitzen  E, Tularemia as a biological weapon, medical and public health management. JAMA. 2001;285:2763–73. DOIPubMedGoogle Scholar
  23. Borio  L, Inglesby  T, Peters  CJ, Schmaljohn  AL, Hughes  JM, Jahrling  PB, Hemorrhagic fevers viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391–405. DOIPubMedGoogle Scholar
  24. Meselson  M, Guillemin  J, Hugh-Jones  M, Langmuir  A, Popova  I, Shelokov  A, The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202–7. DOIPubMedGoogle Scholar
  25. Brookmeyer  R, Blades  N. Prevention of inhalational anthrax in the US outbreak. Science. 2002;295:1861. DOIPubMedGoogle Scholar
  26. Arnon  SS, Schechter  R, Inglesby  TV, Henderson  DA, Bartlett  JG, Ascher  MS, Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70. DOIPubMedGoogle Scholar
  27. Henderson  DA, Inglesby  TV, Bartlett  JG, Ascher  MS, Eitzen  E, Jahrling  PB, Smallpox as a biological weapon: medical and public health management. JAMA. 1999;281:2127–37. DOIPubMedGoogle Scholar
  28. Inglesby  TV, Dennis  DT, Henderson  DA, Bartlett  JG, Ascher  MS, Eitzen  E, Plague as a biological weapon: medical and public health management. JAMA. 2000;283:2281–90. DOIPubMedGoogle Scholar
  29. St Louis  ME, Peck  SH, Bowering  D, Morgan  GB, Blatherwick  J, Banerjee  S, Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med. 1988;108:363–8.PubMedGoogle Scholar
  30. Meltzer  MI, Damon  I, LeDuc  JW, Millar  JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis. 2001;7:959–69. DOIPubMedGoogle Scholar
  31. Gani  R, Leach  S. Transmission potential of smallpox in contemporary populations. Nature. 2001;414:748–51. DOIPubMedGoogle Scholar
  32. Kaplan  EH, Craft  DL, Wein  LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc Natl Acad Sci U S A. 2002;99:10935–40. DOIPubMedGoogle Scholar
  33. Halloran  ME, Longini  IM, Nizam  A, Yang  Y. Containing bioterrorist smallpox. Science. 2002;298:1428–32. DOIPubMedGoogle Scholar
  34. United States Department of Health and Human Services. HHS announces $1.1 billion in funding to states for bioterrorism preparedness. Press release. Jan 31, 2002 [Cited March 2003]. Available from: URL: http://www.hhs.gov/news/press/2002pres/20020131b.html.
  35. United States Department of Health and Human Services. HHS announces bioterrorism aid for states, including special opportunity for advance fund. Press release. Mar 20, 2003 [Cited March 2003]. Available from: URL: http://www.hhs.gov/news/press/2003pres/20030320.html
  36. Bresnitz  EA, DiFerdinando  GT. Lessons from the anthrax attacks of 2001, the New Jersey experience. Clin Occup Environ Med. 2003;2:227–52. DOIGoogle Scholar
  37. National Institute of Allergy and Infectious Diseases Office of Communications and Public Liaison. HHS accelerates bioterrorism research: new programs expedite ideas from concerned scientists. Press release. Dec 6, 2001 [Cited March 2003]. Available from: URL: http://www.niaid.nih.gov/newsroom/releases/accelbio.htm
  38. Smolinski  MS, Hamburg  MA, Lederberg  JA, eds. Microbial threats to health, emergence, detection, and response. Washington: Institute of Medicine National Academies Press; 2003. p. 183–94.

Main Article

1For interval calculations, if reported event dates were discrepant in different case reports, dates reported by Jernigan et al. (13) were used.

Page created: January 10, 2011
Page updated: January 10, 2011
Page reviewed: January 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external